Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Tumors, Malignant Melanoma, Hematological Malignancies, Myelogenous Leukemia, Chronic, Leukemia, Lymphoblastic, Acute
Interventions: Immunoablative Hematopoietic PBSC Transplant, Busulfan pharmacokinetics, Central Nervous System (CNS) prophylaxis radiation; Procedure · Radiation
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Up to 21 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Polycystic Ovary Syndrome (PCOS)
Interventions: Flutamide, Placebo; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Node Positive Breast Cancer
Interventions: Radiation therapy groups; Radiation
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 95 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Breast Cancer
Interventions: 3D printed model; Diagnostic Test
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: BreastCARE; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 74 Years
Enrollment: 1,235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Thinning Hair
Interventions: USPlus DERM Bioactive Fatty Acids 160 mg Softgels, Placebo softgel; Dietary Supplement · Other
Lead sponsor: Ablon Skin Institute Research Center; Other
Eligibility: 25 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Manhattan Beach, California

Conditions: Rheumatoid Arthritis, Osteoarthritis, Periodontal Disease
Interventions: Digital xray of jaw and teeth, Blood draw, questionnaires, Periodontal Examination, Bilateral digital xray of hands; Radiation · Procedure · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 617 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection
Interventions: imiquimod, fluorouracil, questionnaire administration, laboratory biomarker analysis; Drug · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 21 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 6 more

Conditions: Breast Cancer, Gastrointestinal Cancer, Hematologic Cancer
Interventions: OPTIMISE; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Melanoma
Interventions: anti-OX40; Biological
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Cancer, Metastatic, HER2 + Breast Cancer
Interventions: Trastuzumab (Herceptin), SIgnatera; Drug · Diagnostic Test
Lead sponsor: Nagoya City University; Other
Eligibility: 20 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Carlos, Texas

Conditions: Palmoplantar Keratoderma
Interventions: Tapinarof; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Melanoma
Interventions: Hydroxychloroquine (HCQ), Vemurafenib (VEM); Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: HER2Bi-armed activated T cells, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, laboratory biomarker analysis, neoadjuvant therapy, therapeutic conventional surgery; Biological · Drug · Other + 1 more
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Melanoma
Interventions: T-Vec; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Mucopolysaccharidosis IV Type A, Morquio A Syndrome, MPS IVA
Interventions: Imaging, gait analysis, growth, joint test, hearing test, questionnaire, etc.; Diagnostic Test
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Sprain, Strain
Interventions: Ketoprofen Topical Patch 20%; Drug
Lead sponsor: Alkemira SA; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Breast Cancer
Interventions: HER-2 pulsed DC1, trastuzumab, pertuzumab; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Tampa, Florida • Philadelphia, Pennsylvania

Conditions: Systemic Lupus Erythematosus
Interventions: Modafinil; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Acne Vulgaris
Interventions: 50 mg P005672-HCl, Placebo, 100 mg P005672-HCl; Drug
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 12 Years to 45 Years
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 38
States / cities: Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 34 more

Conditions: Leg Ulcer
Interventions: CO2RE® (Syneron Candela Corp, Wayland, MA), Sham laser treatment; Device · Other
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: St Louis, Missouri

Conditions: Rheumatoid Arthritis
Interventions: Etanercept; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Los Angeles, California • Seattle, Washington

Conditions: Dermatomyositis, Polymyositis
Interventions: Acthar; Drug
Lead sponsor: Phoenix Neurological Associates, LTD; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 5
States / cities: Phoenix, Arizona • San Diego, California • Columbia, Missouri + 2 more

Conditions: Hidradenitis Suppurativa
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 24
States / cities: Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 21 more

Search by objective public record fields.

Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])

Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women

Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation

3D Printed Breast Models in the Surgical Management of Breast Cancer

Breast Cancer Risk Reduction: A Patient Doctor Intervention

A 6-month, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of USPlus DERM to Promote Hair Growth in Men and Women With Self-perceived Thinning Hair.

Periodontal Disease and P. Gingivalis in Rheumatoid Arthritis

Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

Improving Comprehensive Care of Cancer Patients

Study of Immune Responses in Patients With Metastatic Melanoma

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment

Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

Neoadjuvant T-VEC in High Risk Early Melanoma

Non-invasive Functional Assessment and Pathogenesis of Morquio A

Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Ankle Sprain or Strain

A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS

Memory and Attention Problems in Lupus: New Treatment Trial With Modafinil

Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris

Evaluating the Safety and Efficacy of Fractionated Carbon Dioxide Therapy in Postoperative Lower Extremity Wound Healing

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis

Dermatomyositis and Polymyositis Registry

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa